Acute effects of isovolemic hemodilution with crystalloids in a canine model of focal cerebral ischemia. 1989

A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
Cerebrovascular Surgery, Massachusetts General Hospital, Boston 02114.

We used 44 splenectomized dogs to study the effects of isovolemic hemodilution with a crystalloid solution. The dogs were randomly divided into a hemodilution and a control group. In each group, 17 dogs were subjected to 6 hours of internal carotid and middle cerebral artery occlusion, and five dogs received sham operations. Isovolemic hemodilution by phlebotomy and Ringer's lactate infusion was performed 30 minutes after arterial occlusion and resulted in an average hematocrit of 32-33%. Hemodilution significantly reduced viscosity, fibrinogen and total protein concentrations, and plasma oncotic pressure. Systemic arterial blood pressure and pulmonary wedge pressure decreased slightly with hemodilution, but central venous pressure and pulmonary arterial pressure did not change significantly. There was a similar decrease in cardiac index in both hemodiluted and control dogs, which may have been due to the effects of barbiturate anesthesia. Intracranial pressure increased significantly with time in all dogs subjected to arterial occlusion, but this increase was significantly more severe in the hemodiluted dogs. Specific gravity, measured just after the dogs were killed, 6 hours after hemodilution, was significantly lower in the white matter and basal ganglia of the left (ischemic) hemisphere in hemodiluted dogs than in controls. Regional cerebral blood flow decreased significantly in the left hemisphere after arterial occlusion. This decrease was almost completely reversed by hemodilution except in the basal ganglia, where the increase in edema caused by hemodilution was the greatest.

UI MeSH Term Description Entries
D007552 Isotonic Solutions Solutions having the same osmotic pressure as blood serum, or another solution with which they are compared. (From Grant & Hackh's Chemical Dictionary, 5th ed & Dorland, 28th ed) Solutions, Isotonic
D008297 Male Males
D010952 Plasma Substitutes Any liquid used to replace blood plasma, usually a saline solution, often with serum albumins, dextrans or other preparations. These substances do not enhance the oxygen- carrying capacity of blood, but merely replace the volume. They are also used to treat dehydration. Blood Expanders,Plasma Volume Expanders,Expanders, Blood,Expanders, Plasma Volume,Substitutes, Plasma,Volume Expanders, Plasma
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D001929 Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6) Brain Swelling,Cerebral Edema,Cytotoxic Brain Edema,Intracranial Edema,Vasogenic Cerebral Edema,Cerebral Edema, Cytotoxic,Cerebral Edema, Vasogenic,Cytotoxic Cerebral Edema,Vasogenic Brain Edema,Brain Edema, Cytotoxic,Brain Edema, Vasogenic,Brain Swellings,Cerebral Edemas, Vasogenic,Edema, Brain,Edema, Cerebral,Edema, Cytotoxic Brain,Edema, Cytotoxic Cerebral,Edema, Intracranial,Edema, Vasogenic Brain,Edema, Vasogenic Cerebral,Swelling, Brain
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D002560 Cerebrovascular Circulation The circulation of blood through the BLOOD VESSELS of the BRAIN. Brain Blood Flow,Regional Cerebral Blood Flow,Cerebral Blood Flow,Cerebral Circulation,Cerebral Perfusion Pressure,Circulation, Cerebrovascular,Blood Flow, Brain,Blood Flow, Cerebral,Brain Blood Flows,Cerebral Blood Flows,Cerebral Circulations,Cerebral Perfusion Pressures,Circulation, Cerebral,Flow, Brain Blood,Flow, Cerebral Blood,Perfusion Pressure, Cerebral,Pressure, Cerebral Perfusion
D003911 Dextrans A group of glucose polymers made by certain bacteria. Dextrans are used therapeutically as plasma volume expanders and anticoagulants. They are also commonly used in biological experimentation and in industry for a wide variety of purposes. Dextran,Dextran 40,Dextran 40000,Dextran 70,Dextran 75,Dextran 80,Dextran B-1355,Dextran B-1355-S,Dextran B1355,Dextran B512,Dextran Derivatives,Dextran M 70,Dextran T 70,Dextran T-40,Dextran T-500,Hemodex,Hyskon,Infukoll,Macrodex,Polyglucin,Promit,Rheodextran,Rheoisodex,Rheomacrodex,Rheopolyglucin,Rondex,Saviosol,Dextran B 1355,Dextran B 1355 S,Dextran T 40,Dextran T 500
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal

Related Publications

A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
June 1997, The Chinese journal of physiology,
A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
May 1991, Stroke,
A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
May 1996, Stroke,
A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
March 1994, Journal of neurosurgery,
A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
December 1985, Journal of neurosurgery,
A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
August 1988, Neurosurgery,
A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
December 1982, JAMA,
A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
September 1988, Critical care medicine,
A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
August 1988, Neurologia medico-chirurgica,
A Hyodo, and R C Heros, and Y K Tu, and C Ogilvy, and R Graichen, and K Lagree, and K Korosue
October 2005, Critical care medicine,
Copied contents to your clipboard!